Bio-Thera Solutions has received approval from its Chinese homeland's National Medical Products Administration (NMPA) for BAT2306, a secukinumab biosimilar, making it the world's first approved biosimilar to Novartis' Cosentyx. Secukinumab is a fully human IgG1 monoclonal antibody (mAb) that selectively inhibits IL-17A, first approved in 2014 for psoriatic arthritis and now indicated across nine immune-mediated diseases including plaque psoriasis, ankylosing spondylitis, hidradenitis suppurativa and polymyalgia rheumatica, with 2025 brand sales of USD 6.668 billion, so the approval opens a large established immunology franchise to biosimilar competition.
For Bio-Thera, BAT2306 extends a biosimilar track record and captures first-mover advantage in a high-volume IL-17A market before peers catch up. According to PharmCube's NextBiopharm database, CSPC's SYS6012 and Celltrion's CT-P55 have also filed secukinumab biosimilar applications but are not yet approved. Click here to request a free trial for NextBiopharm®.

Email us at pmc@pharmcube.com for a free database trial, exclusive reports, or a 1-on-1 consultation